LPAR1 Antikörper (C-Term)

Produktnummer ABIN187787

Der Kaninchen Polyklonal Anti-LPAR1-Antikörper wurde für WB validiert. Er ist geeignet, LPAR1 in Proben von Human und Ratte zu detektieren.

Kurzübersicht für LPAR1 Antikörper (C-Term) (ABIN187787)

Target: LPAR1 (Lysophosphatidic Acid Receptor 1 (LPAR1))

Reaktivität: Human, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser LPAR1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-LPAR1 Antikörper

Bindungsspezifität: C-Term

Spezifität: Reacts with EDG-2. Species Reactivity: Human and Rat. Other species not tested.

Sterilität: 0.2 μm filtered

Immunogen: KLH conjugated synthetic peptide corresponding to the AA 328-344 of human EDG-2.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Rabbit polyclonal antibody against human endothelial cell differentiation gene 2 (CT). This antibody is provided as a 0.2 µm sterile-filtered solution in PBS with 0.08% sodium azide at a concentration of 1 mg/mL. Assayed to be >95% purity by SDS PAGE.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Details zu LPAR1

Target: LPAR1 (Lysophosphatidic Acid Receptor 1 (LPAR1))

Andere Bezeichnung: EDG-2 / LPAR1

Hintergrund: Endothelial cell differentiation gene-2 (EDG-2) receptor is a high affinity receptor for lysophosphatidic acid (LPA). EDG-2, like all other EDG receptors, couple multiple (3 or more) types of G proteins and transduction decreases in c[AMP]i through Gi and increases in [Ca+2]i by augmenting phospholipase C through Gq/11 and beta/gamma dimers and by induction of PI3 kinase, p125 FAK, phospholipase D by activating rho through G12/13. Human EDG-2 is present in high levels on oligodendrocytes and certain human malignant T cell lines. EDG-2 receptors (with EDG-4) may play a role in protecting cardiomyocytes from apoptosis induced by hypoxia and andrenergic stimulation.

Pathways: Myometrial Relaxation and Contraction, Smooth Muscle Cell Migration